LIXT - LIXTE Biotechnology Revamps Leadership, Moves HQ to Florida Amid Growth Strategy

2025-09-03 08:20:46 ET

DENVER, Colo., Sep 03, 2025 ( 247marketnews.com )- LIXTE Biotechnology (NASDAQ:LIXT) is signaling a new phase of corporate evolution with three key leadership appointments and a relocation of its corporate headquarters to Boca Raton, Florida. The changes are part of a broader strategy to streamline operations, strengthen governance, and position the company for future growth in oncology drug development.

The company announced the addition of Lourdes Felix and Guy Primus to its Board of Directors, and named Peter Stazzone as its new Chief Financial Officer. Additionally, Bas van der Baan, former board member, will continue as Chief Scientific Officer, while René Bernards, Ph.D., transitions to Chairman of LIXTE’s Scientific Advisory Board.

CEO and Chairman Geordan Pursglove, who took the helm in June 2025, said the new leadership team brings “exceptional expertise, fresh perspective, and a deep commitment” to the company’s mission of advancing LB-100, its lead anti-cancer compound aimed at enhancing chemotherapy and immunotherapy outcomes.

New CFO Peter Stazzone brings over two decades of financial leadership, with prior experience guiding companies through mergers, capital raises, and public reporting. His resume includes CFO roles at Beyond Commerce, Inc., Strainz, Inc., and Voice Telecom.

Board appointee Lourdes Felix, who will also serve as Chair of the Audit Committee, is currently CEO and CFO of BioCorRx, Inc., and holds board positions at three other Nasdaq-listed firms. She replaces Regina Brown, who retired from LIXTE’s board.

Guy Primus, the second new director, is a veteran technology and innovation executive, previously CEO and co-founder of The Virtual Reality Company, with earlier leadership roles at Starbucks, Microsoft, and within the startup ecosystem. He also chaired the advisory board for Georgia Tech’s School of Industrial and Systems Engineering.

The relocation to Florida, according to Pursglove, “enhances our ability to operate efficiently in a business-friendly environment that reduces costs and is in keeping with our commitment to creating long-term value for shareholders” and reflects LIXTE’s continued commitment to building shareholder value.

As LIXTE progresses with development of LB-100, the company is building out both scientific and operational infrastructure, aligning its leadership and geography to support its pipeline and potential strategic partnerships.

The post LIXTE Biotechnology Revamps Leadership, Moves HQ to Florida Amid Growth Strategy appeared first on 24/7 MarketNews .

For further details see: